Zentalis Pharmaceuticals (NASDAQ:ZNTL) Issues Quarterly Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) issued its earnings results on Thursday. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.14), FiscalAI reports.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock traded up $0.05 during trading hours on Thursday, reaching $5.00. The stock had a trading volume of 701,420 shares, compared to its average volume of 1,656,577. The company has a market cap of $355.93 million, a price-to-earnings ratio of -2.89 and a beta of 1.92. The business’s 50 day moving average price is $4.29 and its 200-day moving average price is $3.58. Zentalis Pharmaceuticals has a 52 week low of $1.21 and a 52 week high of $6.95.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Mizuho began coverage on Zentalis Pharmaceuticals in a report on Friday, July 17th. They issued an “outperform” rating and a $8.00 price target for the company. Guggenheim lifted their target price on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, April 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Rodman & Renshaw started coverage on Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They set a “buy” rating and a $11.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Four research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $6.75.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. ADAR1 Capital Management LLC boosted its stake in Zentalis Pharmaceuticals by 60.0% in the fourth quarter. ADAR1 Capital Management LLC now owns 80,000 shares of the company’s stock valued at $108,000 after acquiring an additional 30,000 shares in the last quarter. Opal Capital LLC acquired a new position in shares of Zentalis Pharmaceuticals during the fourth quarter worth $98,000. Squarepoint Ops LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 405.3% during the 4th quarter. Squarepoint Ops LLC now owns 107,734 shares of the company’s stock valued at $145,000 after purchasing an additional 86,412 shares during the last quarter. Quarry LP boosted its position in shares of Zentalis Pharmaceuticals by 21.4% in the 4th quarter. Quarry LP now owns 132,000 shares of the company’s stock worth $178,000 after purchasing an additional 23,250 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Zentalis Pharmaceuticals by 145.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 173,484 shares of the company’s stock worth $201,000 after purchasing an additional 102,661 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.